Sun Yanming, Zhu Ying, Ye Rui
Critical Care Medicine, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Evid Based Complement Alternat Med. 2022 May 12;2022:7619998. doi: 10.1155/2022/7619998. eCollection 2022.
The efficacy and safety of cisapride in functional constipation (FC) remain unclear. This meta-analysis aimed at investigating the efficacy and safety of cisapride and Maren pill in the treatment of FC. . PubMed, Web of Science, Embase, Cochrane Library, WANFANG DATA, VIP, and CNKI databases were searched from inception to December 2021 for eligible comparative studies investigating the effects and safety of cisapride and Maren pill for FC. The primary outcome was the therapeutic effectiveness rate. The secondary outcomes were recurrence rate and incidence of adverse events.
A total of 526 studies were screened out by searching the electronic databases and by manually searching the relevant reference lists. According to the four-step process (identification, screening, eligibility, and inclusion) to select studies for meta-analysis, 521 articles were excluded. Finally, 5 studies with a total of 414 patients with FC were included in the quantitative analysis after sequential exclusion. The cisapride group had a significantly higher effectiveness rate than the control one (90.78% vs 64.97%, < 0.05). The incidence of adverse events in the cisapride group was lower than that in the Maren pill group (10.08% vs 13.95%, < 0.05). Similarly, the recurrence rate of the cisapride group was lower than that of the Maren pill group (32.31% vs 53.16%, < 0.05).
For FC patients, cisapride is more effective than Maren pill; the recurrence rate and adverse event rate are lower than the latter, which makes it a better choice. The combination of cisapride and Maren pill is a direction of future research studies, which may increase the efficiency and reduce the dosage of cisapride.
西沙必利治疗功能性便秘（FC）的疗效和安全性尚不清楚。本荟萃分析旨在研究西沙必利和麻仁丸治疗FC的疗效和安全性。检索了PubMed、Web of Science、Embase、Cochrane图书馆、万方数据、维普和中国知网数据库，检索时间从建库至2021年12月，以查找关于西沙必利和麻仁丸治疗FC的疗效和安全性的合格对照研究。主要结局为治疗有效率。次要结局为复发率和不良事件发生率。
通过检索电子数据库和手动检索相关参考文献列表，共筛选出526项研究。根据四步流程（识别、筛选、合格性评估和纳入）选择研究进行荟萃分析，排除了521篇文章。最后，经过序贯排除后，纳入5项研究，共414例FC患者进行定量分析。西沙必利组的有效率显著高于对照组（90.78%对64.97%，<0.05）。西沙必利组不良事件发生率低于麻仁丸组（10.08%对13.95%，<0.05）。同样，西沙必利组的复发率低于麻仁丸组（32.31%对53.16%，<0.05）。
对于FC患者，西沙必利比麻仁丸更有效；复发率和不良事件发生率低于后者，使其成为更好的选择。西沙必利与麻仁丸联合使用是未来研究的一个方向，可能会提高疗效并降低西沙必利的用量。
